Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00425945 · ClinicalTrials.gov registry record · NA
Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study
A NA study, sponsored by Stanford University.
- Completed
- Registry status
- NA
- Development phase
- 130
- Enrollment target
NCT00425945: Completed NA study, sponsored by Stanford University.
NCT00425945 is a NA study that has completed, run by Stanford University. The registered enrollment target is 130 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00425945, a NA study, has completed, sponsored by Stanford University.
- COMPLETED
- Registry status
- NA
- Development phase
- 130 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.
Primary Outcome
Mean at Week 12 observation minus mean at Baseline observation.
Interventions
- DRUG Pine Bark Extract (Flavangenol®)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 2006-10 |
| Est. Completion | 2008-08 |
| Phase | NA |
What the finished NCT00425945 record still lists
NCT00425945 is an interventional study that assigns participants to a tested intervention. The registered 130 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (91% lower).
The record links to 0 conditions, and to 1 intervention - of which Pine Bark Extract (Flavangenol®) is the first listed.
NCT00425945 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00425945 about?
NCT00425945 is a clinical study titled "Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study". The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein profile.
What is the current status of trial NCT00425945?
This trial is currently completed. It is a NA study. The enrollment target is 130 participants. The study started on 2006-10. Estimated completion is 2008-08.
What interventions are being tested in trial NCT00425945?
The interventions under investigation include: Pine Bark Extract (Flavangenol®) (DRUG).
Who is sponsoring clinical trial NCT00425945?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00425945's enrollment target sits among peer trials
130 733rd of 2000 higher than 1,257 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01492036 · 130 participants
Long-Term Follow-Up of Recipient of Gene Transfer Research
- NCT01631617 · 130 participants · Phase 2
Effects of Treatments on Atopic Dermatitis
- NCT02368041 · 130 participants
Utility of Thenar Near Infrared Spectroscopy (NIRS) in Pediatric Patients With Heart Failure
- NCT02604277 · 130 participants · NA
Suicidal Behavior in Patients Diagnosed With Bipolar Disorder
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia